U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
RegulatoryapprovedOnswikPositive
AI Analysis
Summary
The FDA approved Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection for type 2 diabetes that reduces injections by over 300 annually compared to once-daily insulin. This approval expands Lilly's type 2 diabetes portfolio with a new long-acting insulin option.
Outcome Details
FDA approves Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection for adults with type 2 diabetes
Importance:9/10
Sentiment:
0.85
FDA approvalinsulintype 2 diabetesonce-weekly injectionbasal insulin
Related Companies
Read the original article
Published by PR Newswire Pharma on September 24, 2026 10:45 AM